Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies

W. Kievit, J. Fransen, E.M. Adang, H.H. Kuper, T.L. Jansen, C.M.A. de Gendt, D.J.R.A.M. de Rooij, H.L.M. Brus, M.A F J van de Laar, P.C.L.M. van Riel

Research output: Contribution to journal › Article › Academic › peer-review